Xenon Pharmaceuticals Quarterly Balance Sheet
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals financial position
As of Jun 30, 2026, Xenon Pharmaceuticals reported total assets of $1.30 billion, up 92.2% from a year earlier against total liabilities of $53.4 million. Shareholders' equity stood at $1.24 billion, or 95.9% of assets. The company held $119.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 21.02, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 119.53M | 545.87M | 199.16M | 104.51M | 135.38M | 116.66M | 142.71M | 87.62M | 136.73M | 58.90M | 148.64M | 99.57M |
| Short-Term Investments | 811.16M | 548.88M | 349.72M | 357.75M | 352.16M | 432.97M | 484.19M | 566.39M | 584.80M | 640.71M | 489.44M | 427.10M |
| Receivables | — | — | — | — | — | — | 1.47M | 938.00K | 853.00K | 833.00K | 874.00K | 805.00K |
| Total Current Assets | 945.87M | 1.11B | 560.65M | 480.14M | 500.25M | 565.54M | 635.26M | 659.64M | 728.09M | 707.20M | 644.96M | 531.01M |
| Property, Plant & Equipment | 7.77M | 8.29M | 8.72M | 8.89M | 9.21M | 9.70M | 10.28M | 10.16M | 10.14M | 9.39M | 9.65M | 10.24M |
| Long-Term Investments | 314.41M | 244.87M | 37.15M | 92.99M | 137.30M | 141.50M | 127.50M | 149.32M | 129.06M | 185.84M | 292.79M | 112.41M |
| Total Assets | 1.30B | 1.39B | 633.16M | 607.84M | 674.28M | 743.28M | 798.14M | 835.90M | 884.01M | 919.02M | 964.80M | 671.09M |
| Accounts Payable | 2.48M | 5.75M | 3.88M | 4.55M | 4.79M | 6.88M | 5.07M | 5.42M | 9.50M | 6.43M | 8.60M | 6.10M |
| Total Current Liabilities | 45.01M | 39.81M | 41.79M | 38.34M | 33.05M | 32.03M | 35.59M | 29.70M | 31.29M | 22.22M | 27.27M | 24.74M |
| Total Liabilities | 53.38M | 48.99M | 51.40M | 48.33M | 40.30M | 39.32M | 43.24M | 38.09M | 39.96M | 31.32M | 36.88M | 34.50M |
| Shareholders' Equity | 1.24B | 1.34B | 581.76M | 559.51M | 633.98M | 703.96M | 754.90M | 797.81M | 844.05M | 887.70M | 927.92M | 636.59M |
| Retained Earnings | -1.46B | -1.35B | -1.25B | -1.14B | -1.05B | -964.52M | -899.47M | -833.78M | -771.00M | -713.07M | -665.14M | -620.40M |
| Net Cash (Debt) | 930.69M | 1.09B | 548.89M | 462.27M | 487.55M | 549.63M | 626.90M | 654.01M | 721.53M | 699.60M | 638.08M | 526.67M |
| Shares Outstanding | 96.75M | 96.62M | 80.01M | 77.12M | 76.94M | 76.59M | 76.42M | 75.79M | 75.67M | 75.46M | 75.37M | 65.00M |
This table shows 12 quarterly periods of Xenon Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow XENE's reporting calendar. What is a balance sheet?